Download PDF
Thromb Haemost 1998; 79(03): 625-630
DOI: 10.1055/s-0037-1614957
Review Articles
Schattauer GmbH

Inhibition of Fibrinogen Binding and Surface Recruitment of GpIIb/IIIa as Dose-Dependent Effects of the RGD-Mimetic MK-852

Kathrin Wittig
1   From the Institute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, Germany
,
Gregor Rothe
1   From the Institute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, Germany
,
Gerd Schmitz
1   From the Institute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, Germany
› Author AffiliationsPresented in part at the 39th Annual Meeting of the Gesellschaft für Throm-bose- und Hämostaseforschung (GTH), Berlin, February 15-18, 1995
Further Information

Publication History

Received 26 February 1997

Accepted after resubmission 05 November 1997

Publication Date:
07 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Conformational activation of platelet GpIIb/IIIa which is coupled to increased affinity for binding of soluble fibrinogen is an important step in platelet aggregation. Antibodies, peptides, and small molecules which antagonise fibrinogen binding, therefore, have been developed as a new class of potent anti-aggregatory compounds. The binding of these artificial ligands, however, similar to fibrinogen binding may also stimulate platelet adhesion and degranulation. Therefore, in this study effects of MK-852, a cyclic hexapeptide based on the RGD-template, on the platelet phenotype were analysed by whole blood flow cytometry. MK-852 already in the nanomolar range completely inhibited the surface binding of fibrinogen to ADP or TRAP-6 stimulated platelets. In the micromolar range, MK-852 induced an up to four-fold increase of GpIIb/IIIa surface expression in the absence of increased P-selectin expression. In conclusion our results suggest that the selective surface recruitment of GpIIb/IIIa may be a side effect of exposure to RGD-analogues which occurs at concentrations well above inhibition of fibrinogen binding.

 

  • References

  • 1 Tschöpe D, Schultheiß HP, Kolarov P, Schwippert B, Dannehl K, Nieuwenhuis HK, Kehrel B, Strauer B, Gries FA. Platelet membrane markers are predictive for increased risk of acute ischaemic events after PTCA. Circulation 1993; 88: 37-42.
    CrossrefPubMedGoogle Scholar
  • 2 Scharf RE, Tomer A, Marzec UM, Teirstein PS, Ruggeri ZM, Harker LA. Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Arterioscler Thromb 1992; 12: 1475-87.
    CrossrefPubMedGoogle Scholar
  • 3 Gawaz M, Neumann FJ, Ott I, Schiessler A, Schömig A. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 1996; 93: 229-37.
    CrossrefPubMedGoogle Scholar
  • 4 Bihour C, Durrieu-Jais C, Besse C, Nurden P, Nurden AT. Flow cytometry reveals activated GP IIb-IIIa complexes on platelets from patients undergoing thrombolytic therapy after acute myocardial infarction. Blood Coagul Fibrinolysis 1995; 6: 395-410.
    CrossrefPubMedGoogle Scholar
  • 5 Hawiger J. Mechanisms involved in platelet vessel wall interaction. Thromb Haemost 1995; 74: 369-72.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Dorahy DJ, Berndt MC, Burns GF. Capture by chemical crosslinkers provides evidence that integrin αIIbβ3 forms a complex with protein tyrosine kinases in intact platelets. Biochem J 1995; 309: 481-90.
    CrossrefPubMedGoogle Scholar
  • 7 Samanen J, Ali F, Romoff T, Calvo R, Sorenson E, Vasko J, Storer B, Berry D, Bennett D, Strohsacker M, Powers D, Stadel J, Nichols A. Development of a small RGD peptide fibrinogen receptor with potent antiaggregatory effect in vitro. J Med Chem 1991; 34: 314-25.
    PubMedGoogle Scholar
  • 8 Ramjit DR, Lynch JJ, Sitko GR, Mellot MJ, Holahan MA, Stabilito II, Stranieri MT, Zhang G, Lynch RJ, Manno PD, Chang CTC, Nutt RF, Brady SF, Veber DF, Anderson PS, Shebuski RJ, Friedman PA, Gould RJ. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis. J Pharmacol Exp Ther 1993; 266: 1501-11.
    PubMedGoogle Scholar
  • 9 Kotzé HF, Badenhorst PN, Lamprecht S, Meiring M, Van Wyk V, Nuyts K, Stassen JM, Vermylen J, Deckmyn H. Prolonged inhibition of acute arterial thrombosis by high dosing of a monoclonal anti-platelet glycoprotein IIb/IIIa antibody in a baboon model. Thromb Haemost 1995; 74: 751-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Carr ME, Carr SL, Hantgan RR, Braaten J. Glycoprotein IIb/IIIa blockade inhibits platelet-mediated force development and reduces gel elastic modulus. Thromb Haemost 1995; 73: 499-505.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Mousa SA, Forsythe M, Lorelli W, Bozarth J, Xue CB, Wityak J, Sielecki TM, Olson RE, DeGrado W, Kapil R, Hussain M, Wexler R, Thoolen MJ, Reilly TM. Novel nonpeptide antiplatelet glycoprotein IIb/IIIa receptor antagonist, DMP754: receptor binding affinity and specificity. Coronary Artery Dis 1996; 7: 767-74.
    CrossrefPubMedGoogle Scholar
  • 12 Coller BS, Anderson K, Weisman HF. New antiplatelet agents: Platelet GPIIb/IIIa antagonists. Thromb Haemost 1995; 74: 302-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Coutré S, Leung L. Novel antithrombotic therapeutics targeted against platelet glycoprotein IIb/IIIa. Annu Rev Med 1995; 46: 257-65.
    CrossrefPubMedGoogle Scholar
  • 14 Frishman WH, Burns B, Atac B, Alturk N, Altajar B, Lerrick K. Novel anti-platelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor. Am Heart J 1995; 130: 877-92.
    CrossrefPubMedGoogle Scholar
  • 15 Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553-9.
    CrossrefPubMedGoogle Scholar
  • 16 Tcheng JE. Enhancing safety and outcomes with the newer antithrombotic and antiplatelet agents. Am Heart J 1995; 130: 673-9.
    CrossrefPubMedGoogle Scholar
  • 17 Vermylen J. Clinical trials of primary and secondary prevention of thrombosis and restenosis. Thromb Haemost 1995; 74: 377-81.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Calvete JJ. Clues for understanding the structure and function of a prototypic human integrin: The platelet glycoprotein IIb/IIIa complex. Thromb Haemost 1994; 72: 1-15.
    PubMedGoogle Scholar
  • 19 Addo JB, Bray PF, Grigoryev D, Faraday N, Goldschmidt-Clermont PJ. Surface recruitment but not activation of integrin αIIbβ3 (GPIIb-IIIa) requires a functional actin cytoskeleton. Arterioscler Thromb Vasc Biol 1995; 15: 1466-73.
    CrossrefPubMedGoogle Scholar
  • 20 Mayo KH, Fan F, Beavers MP, Eckardt A, Keane P, Hoekstra WJ, Andrade-Gordon P. RGD induces conformational transition in purified platelet integrin GPIIb/IIIa-SDS system yielding multiple binding states for fibrinogen γ-chain C-terminal peptide. FEBS Lett 1996; 378: 79-82.
    CrossrefPubMedGoogle Scholar
  • 21 Mohri H, Ohkubo T. “Bridged” peptide of fibrinogen binds to platelets activated by RGD peptide as well as by ADP. Peptides 1994; 15: 683-7.
    CrossrefPubMedGoogle Scholar
  • 22 Satoh T, Kouns WC, Yamashita Y, Kamiyama T, Steiner B. Tetrafibricin, a novel non-peptide fibrinogen receptor antagonist, induces conformational changes in glycoprotein IIb/IIIa. Biochem J 1994; 301: 785-91.
    CrossrefPubMedGoogle Scholar
  • 23 Sanfilippo PJ, Urbanski MJ, Beers KN, Eckardt A, Falotico R, Ginsberg MH, Offord S, Press JB, Tighe J, Tomko K. et al. Novel thiazole-based heterocycles as selective inhibitors of fibrinogen-mediated platelet aggregation. J Med Chem 1995; 38: 34-41.
    CrossrefPubMedGoogle Scholar
  • 24 Brass LF, Ahuja M, Belmonte E, Pizarro S, Tarver A, Hoxie JA. The human platelet thrombin receptor: Turning it on and turning it off. Ann N Y Acad Sci 1994; 714: 1-12.
    CrossrefPubMedGoogle Scholar
  • 25 Negrescu EV, Siess W. Dissociation of the αIIbβ3-integrin by EGTA stimulates the tyrosine kinase pp72(syk) without inducing platelet activation. J Biol Chem 1996; 271: 26547-53.
    CrossrefPubMedGoogle Scholar
  • 26 Suzuki H, Kaneko T, Sakamoto T, Nakagawa M, Miyamoto T, Yamada M, Tanoue K. Redistribution of α-granule membrane glycoprotein IIb/IIIa (integrin αIIbβ3) to the surface of human platelets during the release reaction. J Electron Microsc Tokyo 1994; 43: 282-9.
    PubMedGoogle Scholar
  • 27 Ruan CG, Du XP, Xi XD, Castaldi PA, Berndt MC. A murine glycoprotein Ib complex monoclonal antibody, SZ 2, inhibits platelet aggregation induced by both ristocetin and collagen. Blood 1987; 69: 570-7.
    PubMedGoogle Scholar
  • 28 Marder P. Ligand interactions with the RGD recognition site alter binding of GPIIb-IIIa reactive monoclonal antibody to human platelets. Biochem Biophys Res Commun 1993; 195: 799-806.
    CrossrefPubMedGoogle Scholar
  • 29 Janes SL, Wilson DJ, Cox AD, Chronos NA, Goodall AH. ADP causes partial degranulation of platelets in the absence of aggregation. Br J Haematol 1994; 86: 568-73.
    CrossrefPubMedGoogle Scholar
  • 30 Janes SL, Wilson DJ, Chronos N, Goodall AH. Evaluation of whole blood flow cytometric detection of platelet bound fibrinogen on normal subjects and patients with activated platelets. Thromb Haemost 1993; 70: 659-66.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Abrams CS, Ellison N, Budzynski AZ, Shattil SJ. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 1990; 75: 128-38.
    PubMedGoogle Scholar
  • 32 Woods Jr. VL, Wolff LE, Keller DM. Resting platelets contain a substantial centrally located pool of glycoprotein IIb-IIIIa complex which may be accessible to some but not other extracellular proteins. J Biol Chem 1986; 261: 15242-51.
    PubMedGoogle Scholar
  • 33 Faraday N, Goldschmidt-Clermont PJ, Bray PF. Gender differences in platelet GPIIb-IIIa activation. Thromb Haemost 1997; 77: 748-54.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Huang MM, Lipfert L, Cunningham M, Brugge JS, Ginsberg MH, Shattil SJ. Adhesive ligand binding to integrin αIIbβ3 stimulates tyrosine phosphor-ylation of novel protein substrates before phosphorylation of pp125FAK . J Cell Biol 1993; 122: 473-83.
    CrossrefPubMedGoogle Scholar
  • 35 Tsao PW, Bozarth JM, Jackson SA, Forsythe MS, Flint SK, Mousa SA. Platelet GPIIb/IIIa receptor occupancy studies using a novel fluoresceinated cyclic Arg-Gly-Asp peptide. Thromb Res 1995; 77: 543-56.
    CrossrefPubMedGoogle Scholar